EAM Investors’s Enanta Pharmaceuticals ENTA Stock Holding History

EAM Investors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$517K	Hold	40,952	–	–	0.06%	262
2025 Q4	$646K	Buy	+40,952	New	+$520K	0.07%	245
2022 Q1	–	Sell	-30,839	Closed	-$2.31M	–	313
2021 Q4	$2.31M	Buy	+30,839	New	+$2.42M	0.38%	89
2018 Q3	–	Sell	-6,275	Closed	-$727K	–	321
2018 Q2	$727K	Sell	6,275 -3,863	-38%	-$385K	0.11%	251
2018 Q1	$820K	Buy	+10,138	New	+$780K	0.14%	222
2015 Q1	–	Sell	-74,915	Closed	-$3.81M	–	349
2014 Q4	$3.81M	Buy	74,915 +12,147	+19%	+$544K	0.53%	35
2014 Q3	$2.48M	Sell	62,768 -1,786	-3%	-$71.2K	0.5%	39
2014 Q2	$2.78M	Sell	64,554 -1,292	-2%	-$49.3K	0.53%	28
2014 Q1	$2.63M	Sell	65,846 -1,862	-3%	-$67.6K	0.47%	45
2013 Q4	$1.85M	Buy	+67,708	New	+$1.64M	0.33%	101

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM Investors's ENTA Position: Q1 2026 in Review

EAM Investors held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 40,952 shares worth $517K. The position accounts for 0.06% of the portfolio, ranked #262.

EAM Investors first reported a position in ENTA in Q4 2013 and has held it in 10 quarters since. The position peaked at $3.81M in Q4 2014. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

EAM Investors held 40,952 shares of Enanta Pharmaceuticals worth $517K as of Q1 2026.
EAM Investors left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
Enanta Pharmaceuticals made up 0.06% of EAM Investors's portfolio in Q1 2026, its #262 holding.
EAM Investors first reported a position in Enanta Pharmaceuticals in Q4 2013 and has held it in 10 quarters since.
EAM Investors's Enanta Pharmaceuticals position peaked at $3.81M in Q4 2014.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.